holwichaikawee
Just one large IPO priced this past week, while the other scheduled deal was pulled. Two blank checks also began trading.
Precision medicine company Tempus AI (TEM) priced at the high end to raise $411 million at a $6.4
U.S. IPO Weekly Recap: Precision Medicine IPO Tempus AI Posts A Modest Gain In Its Debut
Summary
- One large IPO priced this past week, while the other scheduled deal was pulled. Two blank checks also began trading - Tempus AI, Telix Pharmaceuticals, Centurion Acquisition, and Perceptive Capital Solutions, respectively.
- One nanocap is currently scheduled to list in the week ahead, although some other small issuers may join the calendar throughout the week - Nova Minerals.
- Street research is expected for one company in the week ahead, and lock-up periods will be expiring for one company.
Renaissance Capital provides pre-IPO research to institutional investors and investment banks. The Firm manages two IPO-focused funds: The Renaissance IPO ETF (NYSE: IPO) and the Renaissance International IPO ETF (NYSE: IPOS). Individual investors can get a free overview of the IPO market on www.renaissancecapital.com, and try a free trial of our premium platform, IPO Pro (ipopro.renaissancecapital.com). Through Renaissance Capital’s pre-IPO research service, institutional investors get an independent opinion, in-depth fundamental analysis, and customizable financial models on all IPOs.